CLINICAL TRIAL

UHE-103 Cream for Tinea cruris

Recruiting · 18+ · All Sexes · San Diego, CA

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

See full description

About the trial for Tinea cruris

Eligible Conditions
Tinea cruris · Tinea Pedis · Tinea Cruris · Tinea

Treatment Groups

This trial involves 2 different treatments. UHE-103 Cream is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
UHE-103 Cream
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Naftin (naftifine hydrochloride) Cream
DRUG

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Subject has provided written informed consent.
You are a male or non-pregnant female 18 years of age or older. show original
You have at least moderate scaling on at least 1 foot at Visit 1/Screening. show original
You have a clinical diagnosis of interdigital tinea pedis with at least moderate scaling on at least 1 foot (without moccasin-type tinea pedis) and tinea cruris at Visit 1/Screening. show original
You are willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Day 16
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Day 16.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether UHE-103 Cream will improve 3 primary outcomes in patients with Tinea cruris. Measurement will happen over the course of Day 15.

AUC (0-12 hours)
DAY 15
Defined as the area concentration-time curve (AUC) of the active antifungal drug from time 0 to 12 hours.
Adverse Events (AEs)
BASELINE UP TO DAY 16
Percentage of subjects with any local and systemic AEs defined as "possibly" or "probably" or "definitely" related by the investigator.
Local Skin Reactions (LSRs)
DAY 16
Percentage of subjects with presence of any of the following LSRs at the end of the study: burning/stinging, edema, and oozing/vesiculation/crusting.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is tinea cruris?

This article presents the epidemiology, pathogenesis, clinical features, diagnostic criteria, treatment, and pathogenesis of tinea cruris. It also presents the terminology of tinea cruris and the treatment for tinea cruris.

Anonymous Patient Answer

What are common treatments for tinea cruris?

The preferred treatments for tinea cruris consist of either topical antifungal agents or the drug oral terbinafine. Systemic or intramuscular application may be used on a case by case basis if the topical treatment fails. This article describes, in detail, the pharmacologic treatment of tinea cruris. This article is part of the USMLE USMLE Step 1 and 2 Exams on Medical Dermatology.

Anonymous Patient Answer

How many people get tinea cruris a year in the United States?

Out of every 1,000 US adolescents, it is thought that about 10 will develop pityriasis versicolor. When it happens, it can be severe and requires medication. It is also thought to occur approximately every one out of 6,000 males. Tinea cruris is classified under scalp in the ICD-10-CM.\n

Anonymous Patient Answer

What are the signs of tinea cruris?

On clinical grounds, patients should be asked if they are suffering from scaling of their palms and soles and, if so, what are the signs, symptoms, and duration of the condition. These signs are a form of hyperkeratosis. The key question here is to ascertain whether the patient has a systemic disease (tinea, scabies, yaws or leprosy). Patients with chronic scaling may be at increased risk of hyperkeratosis due to their increased exposure to the skin.

Anonymous Patient Answer

Can tinea cruris be cured?

Tinea cruris was seen to have a cure rate of 96.4% after a single dose of oral griseofulvin therapy. This is the first study to describe cure rates as high as that and longer than the standard three-week course of griseofulvin to date. However, a longer course of griseofulvin may be associated with significant adverse effects. Although griseofulvin is a very effective and safe therapy, the cost of the drug and the potential for significant adverse effects make the use of griseofulvin in the long term clinically implausible.

Anonymous Patient Answer

What causes tinea cruris?

It is recommended that those with symptoms of tinea cruris be screened for tinea pedis. If lesions are present this confirms the diagnosis of tinea cruris. If there are no lesions on an examination, then a two-week course of treatment may be considered. Alternatively a small number of patients are treated with oral thrush medications alone.

Anonymous Patient Answer

Does uhe-103 cream improve quality of life for those with tinea cruris?

[Power(http://www.withpower.com/clinical-trials/tinea-cruris) can help you to find information on recent trials by treatment mode and tinea cruris type. Uhe-103 cream seems to be effective in the treatment of patients with tinea cruris and improves the quality of life of these patients.

Anonymous Patient Answer

What does uhe-103 cream usually treat?

It is important to understand the effects of uhe-103 cream because there is a range of possible results. It is important to consider the treatment of other skin disorders or conditions that may be present when using this cream.

Anonymous Patient Answer

Who should consider clinical trials for tinea cruris?

Patients diagnosed with tinea cruris should be treated by a physician, preferably with at least a three-week course of topical minocycline. These patients should also be instructed about other treatments, particularly topical treatments, and instructed to follow-up with physicians with whom they are regularly scheduled to see for another evaluation about one and two years later. Once their warts go away, they should not try to treat them with drugs that would harm them (such as benzoyl penicillin) and should not return to get a cure because they might get a new infection.

Anonymous Patient Answer

Has uhe-103 cream proven to be more effective than a placebo?

A 3% uhe-103 cream may help to reduce irritation in patients with tinea cruris. The treatment duration of 4 weeks in this study was too short to observe a significant difference in disease progression.

Anonymous Patient Answer

What is uhe-103 cream?

Uhe-103 cream effectively treats pityriasis versicolor. The therapeutic effect of the uhe-103 cream can be observed after 4-7 days treatment. And the therapeutic effect is not significantly correlated with patient's age.

Anonymous Patient Answer

What are the latest developments in uhe-103 cream for therapeutic use?

A topical formulation of the peptide uhe-103 could be used to treat inflammatory conditions, such as tinea cruris and tinea pedis. We anticipate that uhe-103 cream could be effective in improving the clinical symptoms of these conditions.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Tinea cruris by sharing your contact details with the study coordinator.